One-phase crystal disorder in pharmaceutical solids and its implication for solid-state stability

Journal of Pharmaceutical Sciences

Volumn 100, Issue 10, 2011, Pages 4302-4316

  Clawson, Jacalyn S ^a   Kennedy Gabb, Sonya ^a   Lee, Alfred Y ^a   Copley, Royston C B ^b  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Chemical stability; Disorder; Physical stability; Solid state NMR; Structure property relations (SPR); X ray powder diffractometry

Indexed keywords

3 AMINOCYCLOHEXYL 4 ETHENYL 3 HYDROXY 2,4,7,14 TETRAMETHYL 9 OXOTRICYCLO [5 4 3 0 (1,8)] TETRADEC 6 YL IMIDODICARBONATE; 7 [(4 FLUOROPHENYL) METHYL] 4 HYDROXY N (2 HYDROXYETHYL) 1 METHYL 2 OXO 1,2 DIHYDRO 1,5 NAPHTHYRIDINE 3 CARBOXAMIDE; AMIDE; CARBONIC ACID DERIVATIVE; PLEUROMUTILIN; PROPIONIC ACID; UNCLASSIFIED DRUG; DITERPENE; PROPIONIC ACID DERIVATIVE; TARTARIC ACID DERIVATIVE;

ARTICLE; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; MOLECULAR STABILITY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACEUTICS; SOLID STATE; X RAY DIFFRACTION; CHEMISTRY; COMPARATIVE STUDY; CRYSTALLIZATION; DRUG STABILITY; MASS SPECTROMETRY; MEDICINAL CHEMISTRY; POWDER DIFFRACTION; PROCEDURES; X RAY CRYSTALLOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; CRYSTALLOGRAPHY, X-RAY; DITERPENES; DRUG STABILITY; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; POWDER DIFFRACTION; PROPIONATES; TARTRATES; TECHNOLOGY, PHARMACEUTICAL;

EID: 80052283349     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22621     Document Type: Article

References (42)

1. Shalaev E, Zografi G. 2002. The concept of 'structure' in amorphous solids from the perspective of the pharmaceutical sciences. In Amorphous food and pharmaceutical systems; Levin H, Ed. Cambridge: The Royal Society of Chemistry, pp 11-30.
2. Chamarthy SP, Pinal R. 2008. The nature of crystal disorder in milled pharmaceutical materials. Colloids Surf A Physiochem Eng Aspects 331:68-75.
3. Feng T, Pinal R, Carvajal MT. 2008. Process induced disorder in crystalline materials: Differentiating defective crystals from the amorphous form of griseofulvin. J Pharm Sci 97(8):3207-3221.
4. Suryanarayanan R, Mitchell AG. 1985. Evaluation of two concepts of crystalline using calcium gluceptate as a model compound. Int J Pharm 24:1-17.
5. Chamarthy SP, Pinal R. 2008. The nature of disorder in milled pharmaceutical materials. Colloids Surf A Physiochem Eng Aspects 31(1-2):68-75.
6. Rani M, Govindarajan R, Surana R, Suryanarayanan R. 2006. Structure in dehydrated trehalose dihydrate: Evaluation of the concept of partial crystallinity. Pharm Res 23(10):2356-2367.
7. Byrn SR, Pfeiffer RR, Stephenson G, Grant DJW, Gleason WB. 1994. Solid state pharmaceutical chemistry. Chem Mater 6(8):1148-58.
8. Byrn SR, Xu W, Newman AW. 2001. Chemical reactivity in solid-state pharmaceuticals: Formulation implications. Adv Drug Deliv Rev 48(1):115-136.
9. Ahlneck C, Zografi G. 1990. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int J Pharm 62(2-3):87-95.
10. Byrn SR, Kessler DW. 1987. The solid state reactivity of the crystal forms of hydrocortisone esters. Tetrahedron 43(7):1335-1343.
11. Antonucci V, Yen D, Kelly J, Crocker L, Dienemann E, Miller R, Almarrsson O. 2002. Development of a nanofiltration process to improve the stability of novel anti-MRSA carbapenem drug candidate. J Pharm Sci 91(4):923-932.
12. Giron D. 2005. The active substance as a basis for the stability of drug product. STP Pharma Prat 15(4):314-336.
13. Raijada DK, Saranjiti S, Arvind KB. 2010. Influence of microenvironment pH, humidity, and temperature on the stability of polymorphic and amorphous forms of clopidogrel bisulfate. AAPS PharmSci Tech 11(1):197-203.
14. Raijada DK, Prasad B, Paudel A, Shah RP, Singh S. 2010. Characterization of degradation products of amorphous and polymorphic forms of clopidogrel bisulphate under solid state stress conditions. J Pharm Biomed Anal 52:332-344.
15. Hilden LR, Morris KR. 2004. Physics of Amorphous Solids. J Pharm Sci 93:3-12.
16. Willart JF. Descamps 2008. Solid state amorphization of pharmaceuticals. Mol Pharm 5:905-920.
17. Bhattacharya S, Suryanarayanan R. 2009. Local mobility in amorphous pharmaceuticals: Characterization and implications on stability. J Pharm Sci 98(9):2935-2953.
18. Metz G, Wu X, Smith SO. 1994. Ramped-amplitude cross-polarization in magic-angle-spinning NMR. J Magn Reson A 110:219-227.
19. Antzutkin ON. 1999. Sideband manipulation in magic-angle-spinning nuclear magnetic resonance. Prog Nucl Magn Reson Spectrosc 35:203-266.
20. Fung BM, Khitrin AK, Ermolaev K. 2000. An improved broadband decoupling sequence for liquid crystals and solids. J Magn Reson 142(1):97-101.
21. Herzfeld J, Berger AE. 1980. Sideband intensities in NMR spectra of samples spinning at the magic angle. J Chem Phys 73:6021-6030.
22. Massiot D, Fayon F, Capron M, King I, Le Calvé S, Alonso B, Durand JO, Bujoli B, Gan Z, Hoatson G. 2002. Modelling one- and two-dimensional soilid state NMR spectra. Magn Reson Chem 40:70-76.
23. 13C NMR heteronuclear dipolar-correlation spectroscopy of solids with frequency-switched Lee-Goldburg homonuclear docoupling. J Magn Reson 124(2):516-519.
24. Stahl PH, Sutter B. 2006. Salt selection. In Polymorphism; Hilfiker R, Ed. Weinheim: Wiley-VCH, pp 319.
25. Nyqvist H. 1983. Saturated salt solutions for maintaining specified relative humidities. Int J Pharm Tech Prod Manuf 4:47-48.
26. Shah B, Kakumanu VK, Bansal AK. 2006. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 95(8):1641-1665.
27. Lehto V-P, Tenho M, Vähä-Heikkilä K, Harjunen P, Päällysho M, Välisarri J, Niemelä P, Järvinen K. 2006. The comparison of seven different methods to quantify the amorphous content of spray dried lactose. Powder Technol 167:85-93.
28. ACD/Phys Chem Suite, version 11.00. 2009. Toronto, Ontario, Canada: Advanced Chemistry Development, Inc. Accessed at:.
29. Serajuddin ATM, Pudipeddi M. 2002. Salt-selection strategies. In Handbook of Pharmaceutical Salts Properties, Selection and Use; Stahl PH, Wermuth CG, Eds. New York: Wiley-VCH, pp 135-160.
30. Steed W. 2003. Should solid-state molecular packing have to obey the rules of crystallographic symmetry? Cryst Eng Comm 5:169-179.
31. Steiner T. 2000. Frequency of Z′ values in organic and organometallic crystal structures. Acta Cryst B 56:673-676.
32. Caders S, Lesage A, Pickard CJ, Sautet P, Emsley L. 2009. Characterizing slight structural disorder in solids by combined solid-state NMR and first principles calculations. J Phys Chem A 113:902-911.
33. Byard SJ, Jackson SL, Smail A, Bauer M, Apperley DC. 2005. Studies on the crystallinity of a pharmaceutical development drug substance. J Pharm Sci 94(6):1321-1335.
34. Clawson JC, Vogt FG, Brum J, Sisko J, Patience DB, Dai W, Sharpe S, Jones AD, Pham Tran N, Johnson MN, Copely RCP. 2008. Formation and characterization of crystal containing a pleuromutilin derivative, succinic acid and water. Cryst Growth Des 8 (11):4120-4131.
35. Gu Z, Drueckhammer DG, Kurz L, Liu K, Martin DP, McDermott A. 1999. Solid state NMR studies of hydrogen bonding in a citrate synthase inhibitor complex. Biochemistry 38:8022-8031.
36. Gu Z, Zambrano R, McDermott A. 1994. Hydrogen bonding of carboxyl groups in solid-state amino acids and the peptides: Comparision of carbon chemical shielding, infrared frequencies, and structures. J Am Chem Soc 116:6368-6372.
37. Facelli JC, Gu Z, McDermott A. 1995. Carbon-13 chemical shift tensors of carboxylic acids. GIAO calculations in the acetic acid-methylamine dimmer. Mol Phys 86:865-872.
38. Cosgrove SD, Steele G, Austin TK, Plumb AP, Stensland B, Ferrari E, Roberts KJ. 2005. Understanding the polymorphic behavior of sibenadet hydrochloride through detailed studies integrating structural and dynamical assessment. J Pharm Sci 94(11):2403-2415.
39. Shalaev EY, Zografi G. 1996. Mini review: How does residual water affect solid-state degradation of the amorphous state. J Pharm Sci 85(11):1137-1141.
40. Guerrieri P, Jarring K, Taylor LS. 2010. Impact of counterion on the chemical stability of crystalline salts of procaine. J Pharm Sci 99(9):3719-3730.
41. Peng C, Chan MN, Chan CK. 2001. The hygroscopic properties of dicarboxylic and multifunctional acids: Measurements and UNIFAC predictions. Environ Sci Technol 35(22):4495-4501.
42. Byrn SR, Sutton PA, Tobias B, Frye J, Main P. 1988. The crystal structure, solid-state NMR spectra, and oxygen reactivity of five crystal forms of prednisolone tert-butylacetate. J Am Chem Soc 110:1609-1614.